BlackRock Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

BlackRock Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4.24M	Buy	262,037 +47,005	+22%	+$852K	﹤0.01%	1205
2016 Q3	$3.9M	Buy	215,032 +60,619	+39%	+$1.18M	﹤0.01%	1205
2016 Q2	$2.54M	Buy	154,413 +133,229	+629%	+$2.16M	﹤0.01%	1348
2016 Q1	$351K	Hold	21,184	–	–	﹤0.01%	2256
2015 Q4	$459K	Hold	21,184	–	–	﹤0.01%	2121
2015 Q3	$420K	Sell	21,184 -471,054	-96%	-$14.9M	﹤0.01%	2312
2015 Q2	$17.1M	Buy	+492,238	New	+$15M	0.02%	578
2014 Q3	–	Sell	-89,534	Closed	-$1.42M	–	3745
2014 Q2	$1.42M	Buy	89,534 +60,643	+210%	+$866K	﹤0.01%	1299
2014 Q1	$437K	Buy	28,891 +3,176	+12%	+$35.9K	﹤0.01%	2145
2013 Q4	$196K	Buy	25,715 +1,889	+8%	+$10.2K	﹤0.01%	2664
2013 Q3	$80K	Buy	23,826 +621	+3%	+$1.64K	﹤0.01%	3062
2013 Q2	$57K	Buy	+23,205	New	+$55.7K	﹤0.01%	3133

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors's HZNP Position: Q4 2016 in Review

BlackRock Advisors increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 22% in Q4 2016, buying an estimated $852K and bringing the position to 262,037 shares worth $4.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1205.

BlackRock Advisors first reported a position in HZNP in Q2 2013 and has held it in 12 quarters since. The position peaked at $17.1M in Q2 2015. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

BlackRock Advisors held 262,037 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $4.24M as of Q4 2016.
BlackRock Advisors bought 47,005 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $852K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1205 holding.
BlackRock Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and has held it in 12 quarters since.
BlackRock Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $17.1M in Q2 2015.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.